HORMONET: Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

  • End date
    Jun 28, 2023
  • participants needed
  • sponsor
    H. Lee Moffitt Cancer Center and Research Institute
Updated on 28 October 2022
platelet count
measurable disease
neutrophil count
who 2017
pancreatic net


This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).

Condition Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
Treatment Tamoxifen 20 mg
Clinical Study IdentifierNCT04123262
SponsorH. Lee Moffitt Cancer Center and Research Institute
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Histological diagnosis of well differentiated NET (typical and atypical lung carcinoids, NET G1, NET G2 of all gastroenteropancreatic sites and pancreatic NET G3 according to WHO 2017 classification) 20 advanced / metastatic, inoperable, with no possibility of curative treatment
Immunohistochemical expression ≥ 1 percent for estrogen and / or progesterone receptor
Disease with radiological progression (at least 10 percent tumor volume growth) in the last 12 months before day 1 cycle 1
No possibility of established treatments due to lack of access, risk of toxicities or without clinical indication. Patients who meet criteria for watchful waiting (low-dose disease and non-functioning NET) may be included
Measurable disease
ECOG performance scale 0 to 2
Adequate organic function as defined by the following criteria
serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of local laboratory normality (ULN-LL); (up to 5xULN for participants with liver metastases)
Total serum bilirubin ≤ 2.0 x ULN-LL
Absolute neutrophil count ≥ 1,500 / mm^3
Platelet count ≥ 80,000 / mm^3
Hemoglobin ≥ 9.0 g / dL
Estimated creatinine clearance by the MDRD equation ≥ 30ml / min
Albumin ≥ 3.5 g / dL
INR ≤ 1.5
Term of free and informed consent signed by the patient or legal representative

Exclusion Criteria

Participants already on tamoxifen, but other prior treatment are allowed
Participants with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization)
A history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study
Participants participating in other protocols with experimental drugs
Participants with oral food difficulties
Participants who underwent major recent surgery less than 4 weeks previously
Participants receiving chemotherapy or other oncologic therapy for less than 3 weeks
Participants who use oral anticoagulation
Previous history of deep vein thrombosis or pulmonary embolism in the last 12 months
Pregnant or lactating participants
Participants with postmenopausal vaginal bleeding with no defined etiology
Participants with breast cancer who need to use tamoxifen for this neoplasm
Another synchronous neoplasm that requires systemic treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note